Merck to buy drug developer Pandion Therapeutics for $1.85 billion
The $60-per-share deal represents about 134% premium to Pandion's closing price on Wednesday25-02-2021
25-02-2021
India can look beyond generics: Merck executive
The country can scale in vaccine manufacturing, supply value chain, says Sanat Chattopadhyay, Executive Vice-President and President, Merck Manufacturing Division23-02-2021
Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have been informed by our Registrars and Share Transfer Agent, KFin Technologies Private Limited about the issue of duplicate share certificates as detailed in the attachment.19-02-2021
Coronavirus Vaccine | How Merck, a vaccine titan, lost the COVID race
Merck is now considering a range of options, both in the United States and around the world, mindful that anything it chooses to do would take months to bring to fruition, given the complexity of the manufacturing process11-02-2021
Procter & Gamble Health Ltd - 500126 - Unaudited Financial Results For The Quarter Ended December 31, 2020
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended December 31, 2020 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended December 31, 2020; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2020 furnished by Statutory Auditors of the Company Kindly take the same on record and oblige.10-02-2021
Procter & Gamble Health Ltd - 500126 - Unaudited Financial Results For The Quarter Ended December 31, 2020
We are pleased to inform you that at the meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended December 31, 2020 were approved. We are enclosing herewith the following: a. Unaudited Financial Results for the quarter ended December 31, 2020; b. Press Release; and c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended December 31, 2020 furnished by Statutory Auditors of the Company Kindly take the same on record and oblige.10-02-2021
Long-time Merck CEO Ken Frazier to retire
Among the four Black CEOs to head a Fortune 500 company in the US, Frazier took on Trump for his tacit support of white supremacists05-02-2021
Procter & Gamble Health Ltd - 500126 - Compliance Certificate As Per Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended December 31, 2020.
With reference to the above we are enclosing herewith compliance certificate as per Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended December 31, 2020.02-02-2021
Trailing the first vaccines, next generation turns to coronavirus variants
Imperial is changing the strategy after Merck & Co said Monday it's abandoning development of two experimental Covid vaccines due to lackluster test results27-01-2021
US giant Merck stops development of two COVID-19 vaccine candidates
Both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other COVID-19 vaccines, said Merck25-01-2021